contact us jpkrencn

お知らせ

お知らせ

あなたはここにいる:ホーム > お知らせ

  • 02
    10

    2021

    Pharmacology models for inflammatory immune diseases

    The preclinical pharmacology department of Medicilon has been deeply involved in this field for many years, and has provided a variety of stable and reliable animal models for different targets and pathways for the evaluation of inflammatory immune disease treatments in order for the successful clinical transformation.

  • 01
    01

    2021

    Medicilon Top 10 Greatest Achievements in 2020

    Medicilon embodies its motto of being "Innovation-driven, quality-focused" and keeps on maintaining and improving its technology and quality of services.Among all the positive things occurred in 2020, we chose what we thought was the Top 10 Greatest Achievements, highlighting a successful and productive year Medicilon had in 2020.

  • 12
    28

    2020

    CDMO Service Platform

    Medicilon has constructed the GMP Drug Products Pilot Plant to meet the rising needs for innovative medicine R&D, production, packaging, inspections and stability tests. We are aiming for qualified CDMO services for clients with requirements for the development of innovative medicine.

  • 10
    28

    2020

    Medicilon won two awards at The 15th Award of competitive and trustworthy listed companies.

    Oct 16th, Hainan, China—The 15th Award of competitive and trustworthy listed companies in China was held in Sanya, Hainan. The theme of the forum was “the prospect of the capital market driven by the ‘double cycle’”. 

  • 09
    21

    2020

    Medicilon is honored as TOP 20 R&D CRO Enterprises in China

    Chongqing, September 10, 2020 – 2020 Conference on High Quality Development of Healthcare Industry & the Fifth China Pharmaceutical R&D and Innovation Summit was held successfully